Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert

Forum MINDMAZE THERAPEUTICS N CH1251125998

Watchlist Alert Portefeuille
Koers (CHF) |
1,118  
Range | 1,08 - 1,14
+0,034   (+3,14%)
Volume
61.894
Bied
1,080
Laat
1,140
REL

Relief therapeutics Holding

Volgen
Eerste post
9.108 Posts
vorige pagina 1 ... 451 452 453 454 455 456 volgende pagina
Laatste
Omlaag
    Reactie Reactie van: dd20221227
    2. Reactie Reactie van: dd20221228
    3. Reactie
    4. Reactie Reactie van: dd20221230
    5. Reactie
    6. Reactie Reactie van: dd20221231
    7. Reactie Reactie van: dd20230102
    8. Reactie
    9. Reactie
  9. forum rang 10 DeZwarteRidder
    Pursuant to a Share Subscription Facility agreement (SSF),

    GEM committed to provide up to CHF 50 million to RELIEF

    THERAPEUTICS Holding SA in exchange for registered shares of

    RELIEF THERAPEUTICS Holding SA in the period from

    January 20, 2021, to January 20, 2024, at the discretion of

    RELIEF THERAPEUTICS Holding SA, subject to certain

    exceptions and limitations. No drawdowns have been made

    until December 19, 2022,resulting in a remaining balance of

    the full amount under the SSF of CHF 50 million. GEM's

    purchase position has been calculated using the closing

    price of the registered shares of RELIEF THERAPEUTICS

    Holding SA on SIX Swiss Exchange on December 19, 2022 (CHF

    0.0288) and applying the 10% discount agreed in the SSF

    (resulting in a share price of CHF 0.02592), by dividing the

    remaining balance under the SSF of CHF 50 million by such

    share price of CHF 0.02592. However, according to the

    terms of the SSF, future subscription prices under the SSF

    will correspond to 90% of the average of the closing bid

    prices on SIX Swiss Exchange during the relevant reference

    period, which corresponds to 15 trading days following

    RELIEF THERAPEUTICS Holding SA's relevant subscription

    request, subject to certain exceptions and limitations.

    Therefore, note that the actual subscription price at which

    GEM may be requested to subscribe for registered shares

    of RELIEF THERAPEUTICS Holding SA under the SSF may be lower

    or higher than the share price applied above, and

    accordingly, the number of voting rights GEM may acquire as

    a result thereof may be higher or lower than as set

    forth in this disclosure.
    10. Reactie
    11. Reactie
    12. Reactie Reactie van: dd20230109
    13. Reactie
    14. Reactie Reactie van: dd20230213
    15. Reactie Reactie van: dd20230505
  15. forum rang 10 DeZwarteRidder
    Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
    03.05.2023 / 07:00 CET/CEST

    Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares

    GENEVA (May 3, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases, today announced the implementation timeline for the reverse split of its ordinary shares, which was approved by shareholders at the Extraordinary General Meeting held on April 28, 2023.

    May 4, 2023: Last trading day of old shares on SIX Swiss Exchange
    May 5, 2023: First trading day of new shares on SIX Swiss Exchange

    As previously communicated, shareholdings will be rounded down to the next lower whole number of new merged shares by applying the 400 to 1 exchange ratio. The resulting fractions will be compensated in cash at a fixed price corresponding to the three-day volume-weighted average price of the Relief Therapeutics share on the SIX Swiss Exchange prior to the reverse split.

    Additional information on the reverse split is provided in a Q&A list available here.

    ABOUT RELIEF THERAPEUTICS

    Relief Therapeutics is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief Therapeutics’ portfolio offers a balanced mix of marketed, revenue-generating products, our proprietary, globally patented Physiomimic™ and TEHCLO™ drug delivery platform technologies and a highly targeted clinical development pipeline consisting of risk-mitigated assets focused in three core therapeutic areas: rare metabolic disorders, rare skin diseases and rare respiratory diseases. In addition, Relief Therapeutics is commercializing several legacy products via licensing and distribution partners. Our mission to provide therapeutic relief to those suffering from rare diseases is being advanced by an international team of well-established, experienced biopharma industry leaders with extensive research, development and rare disease expertise. Relief Therapeutics is headquartered in Geneva, with additional offices in Balerna, Switzerland, Offenbach am Main, Germany and Rome. Relief Therapeutics is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, please visit our website www.relieftherapeutics.com or follow Relief Therapeutics on LinkedIn and Twitter
    16. Reactie Reactie van: dd20230522
    17. Reactie Reactie van: dd20230523
    18. Reactie Reactie van: dd20230605
    19. Reactie Reactie van: dd20230901
    20. Reactie Laatste reactie
9.108 Posts
vorige pagina 1 ... 451 452 453 454 455 456 volgende pagina
Laatste
Omhoog

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Forumregels | Lees hier het forumreglement

Kwaliteit boven kwantiteit

Lever een duidelijke en constructieve bijdrage aan de discussie. Kwaliteit trekt kwaliteit aan.

Blijf ontopic

beperk je reactie tot het onderwerp van het forumdraadje en haal er geen andere zaken bij.

Respecteer je medemens

Een afwijkende visie op een bedrijf rechtvaardigt geen persoonlijke aanvallen. Reageer op de inhoud van iemands argumenten, niet op de persoon;

Koop deze belegging bij

naam laatste prijs verschil
MINDMAZE THERAPEUTICS N 1,118 +0,034 +3,14%